RT Journal Article
SR Electronic
T1 Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252150
DO 10.1101/2021.02.22.21252150
A1 Natalia Ortega
A1 Marta Ribes
A1 Marta Vidal
A1 Rocío Rubio
A1 Ruth Aguilar
A1 Sarah Williams
A1 Diana Barrios
A1 Selena Alonso
A1 Pablo Hernández-Luis
A1 Robert A. Mitchell
A1 Chenjerai Jairoce
A1 Angeline Cruz
A1 Alfons Jimenez
A1 Rebeca Santano
A1 Susana Méndez
A1 Montserrat Lamoglia
A1 Neus Rosell
A1 Anna Llupià
A1 Laura Puyol
A1 Jordi Chi
A1 Natalia Rodrigo Melero
A1 Daniel Parras
A1 Pau Serra
A1 Alfredo Mayor
A1 Sonia Barroso
A1 Pilar Varela
A1 Anna Vilella
A1 Antoni Trilla
A1 Pere Santamaria
A1 Carlo Carolis
A1 Marta Tortajada
A1 Luis Izquierdo
A1 Ana Angulo
A1 Pablo Engel
A1 Alberto L. García-Basteiro
A1 Gemma Moncunill
A1 Carlota Dobaño
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252150.abstract
AB Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and its determinants, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 and four HCoV antigens were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed-up for 6 months. Seroprevalence increased over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, were stable over time, except IgG to nucleocapsid antigen and IgM levels that waned. After the peak response, anti-spike antibody levels increased from ∼150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. Pre-existing antibodies to alpha-HCoV were lower in individuals who subsequently seroconverted for SARS-CoV-2. IgG and IgA to HCoV were significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Institut de Salut Global de Barcelona (ISGlobal) internal funds; in-kind contributions of Hospital Clinic de Barcelona, and European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Programme; by the Fundacio Privada Daniel Bravo Andreu; Ministerio de Ciencia e Innovacion through the Centro de Excelencia Severo Ochoa 2019-2023 program (grant number CEX2018-000806-S); and the Catalan Government through the Centres de Recerca de Catalunya program (for P.S.: 2017-SGR-3380 and MINECO RTI2018-093964-B-I00). Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C). G. M. was supported by the Departament de Salut, Generalitat de Catalunya (grant number SLT006/17/00109). L. I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee at HCB (Ref number: HCB/2020/0336).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data used for this analysis will be available and made public under the title of this publication at http://diposit.ub.edu/dspace/ http://diposit.ub.edu/dspace/